X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (18926) 18926
Publication (1036) 1036
Newsletter (246) 246
Book Review (113) 113
Magazine Article (105) 105
Newspaper Article (60) 60
Book Chapter (15) 15
Transcript (12) 12
Conference Proceeding (4) 4
Trade Publication Article (4) 4
Data Set (1) 1
Government Document (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (17419) 17419
prednisone - administration & dosage (11550) 11550
male (11485) 11485
female (10692) 10692
middle aged (7992) 7992
adult (7716) 7716
antineoplastic combined chemotherapy protocols - therapeutic use (5691) 5691
aged (5678) 5678
prednisone - therapeutic use (5371) 5371
vincristine - administration & dosage (5282) 5282
cyclophosphamide - administration & dosage (4959) 4959
index medicus (4652) 4652
prednisone (4330) 4330
doxorubicin - administration & dosage (3902) 3902
treatment outcome (3735) 3735
adolescent (3553) 3553
oncology (3398) 3398
drug therapy, combination (2665) 2665
child (2556) 2556
antineoplastic combined chemotherapy protocols - administration & dosage (2493) 2493
chemotherapy (2346) 2346
hematology (2272) 2272
prednisone - adverse effects (2232) 2232
follow-up studies (2027) 2027
prognosis (1970) 1970
drug administration schedule (1949) 1949
therapy (1883) 1883
corticosteroids (1867) 1867
time factors (1832) 1832
antineoplastic combined chemotherapy protocols - adverse effects (1711) 1711
retrospective studies (1711) 1711
aged, 80 and over (1702) 1702
combined modality therapy (1655) 1655
child, preschool (1574) 1574
remission induction (1499) 1499
methotrexate - administration & dosage (1488) 1488
administration, oral (1463) 1463
cancer (1377) 1377
care and treatment (1366) 1366
rituximab (1331) 1331
glucocorticoids - administration & dosage (1221) 1221
procarbazine - administration & dosage (1186) 1186
bleomycin - administration & dosage (1173) 1173
medicine, general & internal (1166) 1166
cyclophosphamide - therapeutic use (1164) 1164
lymphoma, non-hodgkin - drug therapy (1164) 1164
disease-free survival (1157) 1157
prospective studies (1146) 1146
drug therapy (1139) 1139
dose-response relationship, drug (1133) 1133
recurrence (1103) 1103
neoplasm staging (1048) 1048
survival rate (1042) 1042
hodgkin disease - drug therapy (1039) 1039
lymphoma, large b-cell, diffuse - drug therapy (1037) 1037
immunosuppressive agents - therapeutic use (1021) 1021
survival analysis (1020) 1020
risk factors (1008) 1008
transplantation (1004) 1004
anti-inflammatory agents - administration & dosage (957) 957
glucocorticoids - therapeutic use (935) 935
survival (931) 931
dosage and administration (930) 930
immunosuppressive agents - administration & dosage (930) 930
cyclophosphamide (926) 926
vincristine - therapeutic use (926) 926
prostate cancer (909) 909
cyclophosphamide - adverse effects (901) 901
animals (893) 893
vincristine - adverse effects (883) 883
anti-inflammatory agents - therapeutic use (880) 880
etoposide - administration & dosage (863) 863
infant (857) 857
pediatrics (854) 854
clinical trials as topic (839) 839
trial (824) 824
antineoplastic agents - administration & dosage (806) 806
research (801) 801
biopsy (800) 800
disease (799) 799
multiple myeloma - drug therapy (771) 771
mechlorethamine - administration & dosage (747) 747
children (745) 745
cytarabine - administration & dosage (731) 731
non-hodgkins-lymphoma (728) 728
immunology (725) 725
young adult (711) 711
azathioprine - administration & dosage (707) 707
urology & nephrology (707) 707
surgery (697) 697
docetaxel (688) 688
steroids (687) 687
doxorubicin - adverse effects (686) 686
lymphomas (686) 686
antineoplastic agents - therapeutic use (682) 682
melphalan - administration & dosage (680) 680
dexamethasone - administration & dosage (675) 675
diagnosis, differential (673) 673
medicine & public health (673) 673
doxorubicin - therapeutic use (664) 664
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (16793) 16793
German (517) 517
French (415) 415
Spanish (350) 350
Japanese (337) 337
Polish (303) 303
Chinese (178) 178
Italian (148) 148
Russian (100) 100
Dutch (42) 42
Czech (38) 38
Danish (25) 25
Portuguese (24) 24
Romanian (22) 22
Hungarian (16) 16
Hebrew (15) 15
Norwegian (8) 8
Serbian (7) 7
Finnish (5) 5
Bulgarian (4) 4
Slovak (4) 4
Croatian (3) 3
Swedish (3) 3
Bosnian (1) 1
Korean (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 12/2007, Volume 357, Issue 25, pp. 2562 - 2575
This study examines the toxicity of immunosuppressive regimens in renal-transplant recipients. A regimen containing mycophenolate mofetil, daclizumab, low-dose... 
MULTICENTER TRIAL | MEDICINE, GENERAL & INTERNAL | CYCLOSPORINE MICROEMULSION | EFFICACY | KIDNEY-TRANSPLANTATION | IMMUNOSUPPRESSION | ALLOGRAFT RECIPIENTS | TACROLIMUS | MYCOPHENOLATE-MOFETIL | SIROLIMUS | NEPHROTOXICITY | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Adrenal Cortex Hormones - therapeutic use | Enzyme Inhibitors - administration & dosage | Antibodies, Monoclonal, Humanized | Calcineurin Inhibitors | Treatment Failure | Adult | Diabetes Mellitus - etiology | Female | Drug Therapy, Combination | Mycophenolic Acid - administration & dosage | Immunosuppressive Agents - administration & dosage | Sirolimus - adverse effects | Tacrolimus - administration & dosage | Prednisone - administration & dosage | Glomerular Filtration Rate | Graft Rejection - prevention & control | Kaplan-Meier Estimate | Kidney Transplantation | Immunoglobulin G - administration & dosage | Opportunistic Infections | Sirolimus - administration & dosage | Mycophenolic Acid - analogs & derivatives | Antibodies, Monoclonal - administration & dosage | Cyclosporine - administration & dosage | Immunosuppressive Agents - adverse effects | Aged | Adrenal Cortex Hormones - administration & dosage | Transplantation | Corticosteroids | Kidneys | Research | Health aspects | Immunosuppressive agents | Medical research | Immunology | Inhibitor drugs | Transplants & implants | Toxicity | Inhibidors enzimàtics | Posologia | Ús terapèutic | Corticosteroides | Rebuig (Biologia) | Posology | Therapeutic use | Immunosupressive agents | Graft rejection | Trasplantament renal | Enzyme inhibitors | Adrenocortical hormones | Immunosupressors | Kidney transplantation | Tacrolimus: administration & dosage | Medical and Health Sciences | Graft Rejection: prevention & control | Immunoglobulin G: administration & dosage | Medicin och hälsovetenskap | Mycophenolic Acid: administration & dosage | Antibodies | Klinisk medicin | Monoclonal: administration & dosage | Prednisone: administration & dosage | Adrenal Cortex Hormones: administration & dosage | Immunosuppressive Agents: administration & dosage | Mycophenolic Acid: analogs & derivatives | Sirolimus: administration & dosage | Cyclosporine: administration & dosage | Calcineurin: antagonists & inhibitors | Diabetes Mellitus: etiology | Urologi och njurmedicin | Sirolimus: adverse effects | Adrenal Cortex Hormones: therapeutic use | Enzyme Inhibitors: administration & dosage | Immunosuppressive Agents: adverse effects | Clinical Medicine | Immunosuppressive Agents: therapeutic use | Urology and Nephrology
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2016, Volume 34, Issue 11, pp. 1175 - 1181
Journal Article
The Lancet Oncology, ISSN 1470-2045, 08/2017, Volume 18, Issue 8, pp. 1076 - 1088
The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-adjusted International Prognostic Index [aa-IPI] score 2 or 3) treated... 
CLINICAL-PRACTICE GUIDELINES | SURVIVAL | SUPPORT | IMPACT | CONSOLIDATION | RESPONSE CRITERIA | ONCOLOGY | R-CHOP | NON-HODGKIN-LYMPHOMA | ELDERLY-PATIENTS | MEGACHOEP | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Consolidation Chemotherapy | Cyclophosphamide - adverse effects | Lymphoma, Large B-Cell, Diffuse - therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Intention to Treat Analysis | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Carmustine - administration & dosage | Stem Cell Transplantation - adverse effects | Stem cells
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2016, Volume 34, Issue 17, pp. 2020 - 2027
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 12, pp. 1188 - 1194
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2017, Volume 35, Issue 16, pp. 1786 - 1794
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2010, Volume 362, Issue 11, pp. 975 - 985
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2013, Volume 368, Issue 15, pp. 1408 - 1416
A dose-intense infusional chemotherapy program plus rituximab had a high degree of efficacy in patients with primary mediastinal B-cell lymphoma, which is... 
MEDICINE, GENERAL & INTERNAL | AMPLIFICATION | MANAGEMENT | EFFICACY | DOXORUBICIN | SCLEROSIS | CLASSICAL HODGKIN LYMPHOMA | RADIOTHERAPY | EXPRESSION | GERMINAL-CENTER | CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Filgrastim | Dose-Response Relationship, Drug | Young Adult | Vincristine - administration & dosage | Adult | Female | Retrospective Studies | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Kaplan-Meier Estimate | Rituximab | Stroke Volume - drug effects | Etoposide - administration & dosage | Recombinant Proteins - administration & dosage | Disease-Free Survival | Vincristine - adverse effects | Aged | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Granulocyte Colony-Stimulating Factor - administration & dosage | Drugs | Dose-response relationship (Biochemistry) | Usage | Cyclophosphamide | Patient outcomes | Dosage and administration | Lymphomas | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | Doxorubicin | Medical research | Nuclear magnetic resonance--NMR | Disease | Review boards | Genes | Etoposide | Prednisone | Radiation therapy | Kinases | Vincristine | Patients | Morbidity | Chemotherapy | Lymphocytes B | Remission | Mutation | Hodgkin's disease | B-cell lymphoma
Journal Article
British Journal of Haematology, ISSN 0007-1048, 05/2014, Volume 165, Issue 4, pp. 534 - 544
Summary The purpose of this national retrospective study was to evaluate the outcome in children with relapsed or primary refractory Hodgkin lymphoma [HL]... 
refractory disease | relapse | children | survival | Hodgkin lymphoma | Relapse | Children | Refractory disease | Survival | COMBINED-MODALITY THERAPY | PROGNOSTIC-FACTORS | RADIATION | CHEMOTHERAPY | TRIAL | FRENCH SOCIETY | DISEASE | SALVAGE THERAPY | RADIOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Procarbazine - administration & dosage | Prednisolone - adverse effects | Recurrence | Cyclophosphamide - administration & dosage | Prednisolone - administration & dosage | Follow-Up Studies | Humans | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Hodgkin Disease - surgery | Hodgkin Disease - mortality | Vincristine - administration & dosage | Child | Dacarbazine - administration & dosage | Dexamethasone - administration & dosage | Hematopoietic Stem Cell Transplantation | Etoposide - administration & dosage | Combined Modality Therapy | Bleomycin - administration & dosage | Remission Induction | Cytarabine - administration & dosage | Ifosfamide - administration & dosage | Adolescent | Vincristine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Cisplatin - administration & dosage | Hodgkin Disease - radiotherapy | Multicenter Studies as Topic | Hodgkin Disease - drug therapy | Retrospective Studies | Radiotherapy, Adjuvant | Doxorubicin - administration & dosage | Chlorambucil - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Ifosfamide - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Clinical Trials as Topic | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Carmustine - administration & dosage | Patient outcomes | Diseases
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2017, Volume 377, Issue 4, pp. 338 - 351
Journal Article
Annals of Oncology, ISSN 0923-7534, 03/2011, Volume 22, Issue 3, pp. 664 - 670
Journal Article